Kyleena

Levonorgestrel, the active ingredient in Kyleena, is a progestin presented as a 52 mg intrauterine system (IUS) for intrauterine use. It provides continuous local hormone release that suppresses ovulation, thickens cervical mucus, and induces endometrial changes, thereby preventing pregnancy for women of reproductive age in the EU market.

GNH USA supplies Kyleena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with capabilities for regulatory‑approved distribution and product support across multiple regions and ensuring compliance with local health authority requirements.

Kyleena, a levonorgestrel intrauterine system, is indicated for hormonal contraception.

Contraception (prevention of pregnancy): provides highly effective reversible birth control for women of reproductive age. Extended‑duration contraception (up to 5 years): maintains contraceptive efficacy for up to five years after insertion. Hormonal birth control for women seeking a non‑daily method: delivers continuous low‑dose levonorgestrel locally, avoiding systemic hormone fluctuations.

Kyleena may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Irregular bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or abdominal pain - Cramping after insertion - Headache - Breast tenderness

Serious or Rare Side Effects: - Uterine perforation during insertion - Pelvic infection (e.g., PID) - Ectopic pregnancy if contraception fails - Expulsion of the device - Allergic reaction to device components

Before using Kyleena, several safety considerations should be reviewed.

Pregnancy testing: confirm non‑pregnant status before insertion. Breastfeeding: discuss risks, as levonorgestrel may be excreted in milk. Uterine anomalies: evaluate for abnormalities that may increase insertion complications. History of pelvic infection: assess risk of post‑insertion infection. Smoking: advise cessation, especially in women over 35, due to thrombotic risk. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Kyleena can be affected by other medicines.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin) may reduce levonorgestrel efficacy. - Concurrent systemic hormonal contraceptives could interfere with local hormone release. - Rifampin or griseofulvin may decrease contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Ketoconazole and other strong antifungals may modestly lower hormone levels. - St. John’s wort herbal supplement may slightly reduce efficacy.